Expertise in
46
conditions

Charles M. Lourenco

Sao Jose Do Rio Preto, SP, BR 
Expertise in
46
conditions
Sao Jose Do Rio Preto, SP, BR 
OverviewLocationsClinical Research

Overview

Charles Lourenco practices in Sao Jose Do Rio Preto, Brazil. Mr. Lourenco is highly rated in 46 conditions, according to our data. His top areas of expertise are Niemann-Pick Disease, Acute Cerebellar Ataxia, Drug Induced Dyskinesia, and Spasticity.

His clinical research consists of co-authoring 130 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Sao Jose Do Rio Preto, SP, Brazil
Other Locations
Ribeirao Preto, SP 14096160, Brazil
Av. Duque De Caxias Norte 225, Pirassununga, SP 13635900, Brazil
Rio De Janeiro, RJ, Brazil
Sao Jose, PB 15090000, Brazil
Belo Horizonte, MG, Brazil
Sao Paulo, SP, Brazil
Porto Alegre, RS, Brazil
Avenue Bandeirantes 3900, Paulistania, SP 14049900, Brazil

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy
A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy
Enrollment Status: Active_not_recruiting
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: SHP611
Study Phase: Phase 2
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drugs: PRX-102 (Pegunigalsidase Alfa), Agalsidase Beta
Study Phase: Phase 3
Biomarker for Pompe Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGI-CAL PROTOCOL
Biomarker for Pompe Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGI-CAL PROTOCOL
Enrollment Status: Withdrawn
Publish Date: February 13, 2023
Biomarker for Fabry Disease: BioFabry AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL
Biomarker for Fabry Disease: BioFabry AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL
Enrollment Status: Withdrawn
Publish Date: February 13, 2023
Biomarker for Morquio Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL
Biomarker for Morquio Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL
Enrollment Status: Withdrawn
Publish Date: February 13, 2023
Biomarker for Krabbe Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGI-CAL PROTOCOL
Biomarker for Krabbe Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGI-CAL PROTOCOL
Enrollment Status: Withdrawn
Publish Date: February 13, 2023
Biomarker for Gilbert Disease - An International, Multi- Center, Epidemiological Protocol
Biomarker for Gilbert Disease - An International, Multi- Center, Epidemiological Protocol
Enrollment Status: Withdrawn
Publish Date: February 13, 2023
Biomarker for Niemann Pick Type C Disease (NPC1/NPC2) an International, Multicenter, Epidemiological Study
Biomarker for Niemann Pick Type C Disease (NPC1/NPC2) an International, Multicenter, Epidemiological Study
Enrollment Status: Withdrawn
Publish Date: February 13, 2023
Biomarker for Gaucher Disease an International, Multicenter, Epidemiological Protocol
Biomarker for Gaucher Disease an International, Multicenter, Epidemiological Protocol
Enrollment Status: Withdrawn
Publish Date: February 13, 2023
Biomarker for Maroteaux-Lamy Disease: BioMaroteaux-Lamy AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL
Biomarker for Maroteaux-Lamy Disease: BioMaroteaux-Lamy AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL
Enrollment Status: Withdrawn
Publish Date: February 13, 2023
View 9 Less Clinical Trials

130 Total Publications

Practical recommendations for diagnosis, management, and follow-up of Niemann-Pick type-C disease patients: a Brazilian perspective.
Practical recommendations for diagnosis, management, and follow-up of Niemann-Pick type-C disease patients: a Brazilian perspective.
Journal: Arquivos de neuro-psiquiatria
Published: May 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lourenco's expertise for a condition
ConditionClose
    View All 40 Advanced Conditions
    View All 70 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile